The impact of axillary lymph nodes removed in staging of node-positive breast carcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue 5, 2006, Pages 1328-1334

  Kuru, Bekir ^a   Bozgul, Mustafa ^a  

^a ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Lymph node positive breast carcinoma; removed axillary nodes; staging of breast carcinoma

Indexed keywords

BIOMEDICAL ENGINEERING; CHEMOTHERAPY; PATHOLOGY; RADIOTHERAPY; TUMORS;

COMBINED CHART AUDIT WITH FEEDBACK (C-AWF),; REMOVED AXILLARY NODES; STAGING OF BREAST CARCINOMA;

ONCOLOGY;

TAMOXIFEN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL RECORD; PRIORITY JOURNAL;

ADULT; AGED; ANALYSIS OF VARIANCE; AXILLA; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY, MODIFIED RADICAL; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES;

EID: 33751167017     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.07.015     Document Type: Article

References (41)

1. Singletary S.E., Allred C., Ashley P., et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20 (2002) 3628-3636
2. Carter C.L., Allen C., and Henson D.E. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63 (1989) 181-187
3. Hagan M.P., and Mendenhall N.P. Adjuvant therapy after modified radical mastectomy. In: Bland K.I., and Copeland E.M. (Eds). The breast: Comprehensive management of benign and malignant diseases. 2nd ed. (1998), W.B. Saunders Company, Philadelphia, PA 1160-1171
4. Fisher B., Redmond C., Fisher E.R., et al. Ten-year results of a randomized trial comparing radical mastectomy and total mastectomy with and without radiation. N Engl J Med 312 (1985) 674-681
5. Axelsson C.K., Mouridsen H., and Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. Eur J Cancer 28A (1993) 1415-1418
6. Mathiesen O., Carl J., Bonderup O., et al. Axillary sampling and the risk of erroneous staging of breast cancer. Analysis of 960 consecutive patients. Acta Oncol 29 (1990) 721-725
7. Kricuta C.I., and Tausch J. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in breast carcinoma. Cancer 69 (1992) 2496-2501
8. Fisher B., Wolmark N., Bauer N., et al. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 152 (1981) 765-772
9. Somner J.E.A., Dixon J.M.J., and Thomas J.S.J. Node retrieval in axillary lymph node dissections. Recommendations for a minimum numbers to be confident about node negative status. J Clin Pathol 57 (2004) 845-848
10. Iyer R.V., Hanlon A., Fowble B., et al. Accuracy of the extent of axillary nodal positivity related to primary tumor size, number of involved nodes, and number of nodes examined. Int J Radiat Oncol Biol Phys 47 (2000) 1177-1183
11. Goldhirsch A., Glick J.H., Gelber R.D., et al. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16 (2005) 1569-1583
12. Recht A., Edge S.B., Solin L.J., et al. Postmastectomy radiotherapy: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 (2001) 1539-1569
13. Schaapveld M., Otter R., de Vries E.G.E., et al. Variability in axillary lymph node dissection for breast cancer. J Surg Oncol 87 (2004) 4-12
14. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer. Experience from a large study with long-term follow-up. Histopathology 19 (1991) 403-410
15. Wilking N., Rutqvist L.E., Carsten A., et al. Prognostic significance of axillary nodal status in primary breast cancer in relation to the number of resected nodes. Acta Oncol 3 (1992) 29-35
16. Willemse P.H., Otter R., Schaapveld M., et al. Quality analysis of axillary lymph node dissection in breast cancer patients in the northern part of The Netherlands. [Abstract]. Proc Am Soc Clin Oncol (1999) ASCO annual meeting.
17. Studer U.E., Scherz S., Scheidegger J., et al. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastasis. J Urol 144 (1990) 243-245
18. Rosen P.P., Lesser M.L., Kinne D.W., et al. Discontinuous or skip metastases in breast carcinoma. Ann Surg 197 (1983) 276-283
19. Petrik D.W., McReady D.R., Sawka C.A., et al. Association between extent of axillary lymph node dissection and patient, tumor, surgeon, and hospital factors in patients with early breast cancer. J Surg Oncol 82 (2003) 84-90
20. Saha S., Farrar W.B., Young D.C., et al. Variation in axillary node dissection influences the degree of nodal involvement in breast cancer patients. J Surg Oncol 73 (2000) 134-137
21. Larson D., Weinstein M., Goldberg I., et al. Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys 12 (1986) 1575-1582
22. Kiel K.D., and Rademacker A.W. Early-stage breast cancer: Arm edema after wide excision and breast irradiation. Radiology 198 (1996) 279-283
23. Suneson B.L. Clinical incidence of lymphedema in breast cancer patients in Jonkoping County, Sweden. Eur J Cancer Care 5 (1996) 1-12
24. Edwards T.L. Prevalence and aetiology of lymphedema after breast cancer treatment in Southern Tasmania. Aust N Z J Surg 70 (2000) 412-418
25. Ozaslan C., and Kuru B. Lymphedema after treatment of breast cancer. Am J Surg 187 (2004) 69-72
26. Tominaga T., Takashima S., Danno M., and Modified Radical Mastectomy Study Group. Randomized clinical trial comparing level II and III axillary node dissection in addition to mastectomy for breast cancer. Br J Surg 91 (2003) 38-43
27. Joslyn S.A., and Konety B.R. Effect of axillary lymphadenectomy on breast carcinoma survival. Breast Cancer Res Treat 91 (2005) 11-18
28. Vinh-Hung V., Cserni G., Burzykowski T., et al. Effect of the number of uninvolved nodes on survival in early breast cancer. Oncol Reports 10 (2003) 363-368
29. Giuliano A.E., Dale P.S., Turner R.R., et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 222 (1995) 394-395
30. Guenther J.M. Axillary dissection after unsuccessful sentinel lymphadenectomy for breast cancer. Am Surg 65 (1999) 991-994
31. McMasters K.M. The eternally enigmatic axilla: Further controversy about axillary lymph nodes in breast cancer. Ann Oncol 10 (2003) 1128-1130
32. Jatoi I., Hilsenbeck S.G., Clark G.M., et al. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol 17 (1999) 2334-2340
33. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19 (2001) 602-611
34. Rodenhuis S., Bontenbal M., Beex L.V., et al., Netherlands Working Party on Autologous Transplantation in Solid Tumors. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349 (2003) 7-16
35. U.S. National Institutes of Health. Adjuvant doxorubicin, cyclophosphamide, and paclitaxel in treating patients with breast cancer. Conditions: Stage I breast cancer; stage II breast cancer; stage IIIA breast cancer; stage IIIC breast cancer; male breast cancer. Available at: http://www.clinicaltrials.gov/ct/show/NCT00070564?order=1. Accessed August 4, 2006.
36. Kuru B., Camlibel M., Dinc S., et al. Prognostic significance of apex axillary invasion for locoregional recurrence and effect of postmastectomy radiotherapy on overall survival in node positive breast cancer patients. World J Surg 28 (2004) 236-241
37. Eifel P., Axelson J.A., Costa J., et al. National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93 (2001) 979-989
38. Whelan T.J., Julian J., Wright J., et al. Does locoregional radiation therapy improve survival in breast cancer?. A meta-analysis. J Clin Oncol 18 (2000) 1220-1229
39. Overgaard M., Hansen P.S., Overgaard J., et al., Danish Breast Cancer Cooperative Group 82b Trial. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 337 (1997) 949-955
40. Ragaz J., Olivotto I.A., Spinelli J.J., et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomised trial. J Natl Cancer Inst 97 (2005) 116-126
41. Sigurdson E.R. Lymph node dissection: Is it diagnostic or therapeutic. J Clin Oncol 21 (2003) 965-967